Efficacy Study of T Cell Depleted Allogeneic Non-myeloablative Stem Cell Transplant

Inclusion Criteria

• •Subjects must have their diagnosis confirmed at the transplant center.
• •Performance status must be Cancer and Leukemia Group B (CALGB) = 0, 1, or 2.
• •Subjects must have a 3-6/6 human leukocyte antigen (HLA)-matched related donor or 8/8 or better allele level match matched unrelated donor (MUD) (at A,B, C, DRB1, DQ).
• •HIV negative.
• •Women of child bearing potential must have a negative pregnancy test within 1 week of starting therapy.
• •Subjects \> or equal to 18 years of age are eligible.
• •Subjects must have a Multi Gated Acquisition Scan (MUGA) and/or Echocardiography (ECHO) or cardiac magnetic resonance (MR) and or diffusing capacity testing of the lung for carbon monoxide (DLCO) performed before transplant.
• •Specific populations:
• •* Group A) Subjects with a high chance of progressive lymphoid or myelomatous diseases.
• •* Group B) Subjects with a high chance of progressive myeloid diseases, marrow failure syndromes or myeloproliferative disorders
• •1. Donor must be capable of providing informed consent. If 14-17 years of age, a 'single patient exemption' from the local Institutional Review Board must be obtained.
• •2. Donor must not have any medical condition which would make mobilization or apheresis more than a minimal risk, and should have the following:
• •1. Adequate cardiac function by history and physical examination. Those with a history of cardiac failure or infarction should be evaluated by a cardiologist prior to donation
• •2. Adequate hematopoietic function with hematocrit ≥ 30%, white blood cell count of 3000, and platelets 100,000.
• •3. Females should not be pregnant or lactating and have a negative serum pregnancy test within 1 week of beginning mobilization if of child bearing potential.